Dokumentdetails
ID
doi:10.1038/s41419-023-05922-w...
Autor
Yang, Yang Xu, GaosiLangue
enEditor
Nature
Kategorie
Life Sciences
Jahr
2023
Auflistungsdatum
05.07.2023
Schlüsselwörter
26 patients sars-cov-2 cancer icisZusammenfassung
Cancer patients are susceptible to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
Different antitumor treatments have attracted wide attention in the context of coronavirus disease 2019 (COVID-19), especially immune checkpoint inhibitors (ICIs) that have revolutionized oncology changes.
It may also have protective and therapeutic roles in viral infections.
In this article, we collected 26 cases of SARS-CoV-2 infection during ICIs therapy and 13 related to COVID-19 vaccination from Pubmed, EMBASE, and Wed of Science.
Of these 26 cases, 19 (73.1%) presented mild cases and 7 (26.9%) were severe cases.
Melanoma (47.4%) was a common cancer type in mild cases and lung cancer (71.4%) in severe cases ( P = 0.016).
The results showed that their clinical outcomes varied widely.
Although there are similarities between the immune checkpoint pathway and COVID-19 immunogenicity, ICIs therapy overactivated T cells, which often leads to immune-related adverse events.
In fact, the COVID-19 vaccine has been shown to be safe and effective in patients treated with ICIs.
In this review, we report the vital clinical observations of SARS-CoV-2 infection or vaccination in cancer patients treated with ICIs and explore the potential interaction between them.
Yang, Yang,Xu, Gaosi, 2023, SARS-CoV-2 infection and COVID-19 vaccination in cancer patients undergoing immune checkpoint inhibitors, Nature
Systematic Feature Design for Cycle Life Prediction of Lithium-Ion Batteries During Formation
cycle prediction framework feature design features life formation
